CR20230566A - Derivados de triazina y su uso en el tratamiento del cáncer - Google Patents
Derivados de triazina y su uso en el tratamiento del cáncerInfo
- Publication number
- CR20230566A CR20230566A CR20230566A CR20230566A CR20230566A CR 20230566 A CR20230566 A CR 20230566A CR 20230566 A CR20230566 A CR 20230566A CR 20230566 A CR20230566 A CR 20230566A CR 20230566 A CR20230566 A CR 20230566A
- Authority
- CR
- Costa Rica
- Prior art keywords
- sup
- cancer
- treatment
- triazine derivatives
- compounds
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000003918 triazines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invención se refiere a compuestos novedosos que tienen la fórmula general Ib, en donde R1, R2, R3, R4, R5 y Z son como se describen en la presente, una composición que incluye los compuestos y métodos para usar los compuestos.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21177660 | 2021-06-04 | ||
EP21188639 | 2021-07-30 | ||
EP21215875 | 2021-12-20 | ||
PCT/EP2022/064995 WO2022253936A1 (en) | 2021-06-04 | 2022-06-02 | Triazine derivatives and their use in the treatment of cancer. |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20230566A true CR20230566A (es) | 2024-01-22 |
Family
ID=82115763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20230566A CR20230566A (es) | 2021-06-04 | 2022-06-02 | Derivados de triazina y su uso en el tratamiento del cáncer |
Country Status (16)
Country | Link |
---|---|
US (1) | US20240132471A1 (es) |
EP (1) | EP4347571A1 (es) |
JP (1) | JP2024522494A (es) |
KR (1) | KR20240019083A (es) |
AR (1) | AR126053A1 (es) |
AU (1) | AU2022287224A1 (es) |
BR (1) | BR112023025318A2 (es) |
CA (1) | CA3216026A1 (es) |
CL (1) | CL2023003491A1 (es) |
CO (1) | CO2023016212A2 (es) |
CR (1) | CR20230566A (es) |
IL (1) | IL307201A (es) |
MX (1) | MX2023013998A (es) |
PE (1) | PE20240928A1 (es) |
TW (1) | TW202313577A (es) |
WO (1) | WO2022253936A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
TW202327604A (zh) * | 2022-01-07 | 2023-07-16 | 大陸商藥捷安康(南京)科技股份有限公司 | Nlrp3發炎小體抑制劑及其應用 |
WO2024017924A1 (en) * | 2022-07-21 | 2024-01-25 | F. Hoffmann-La Roche Ag | Nlrp3 inhibitors |
WO2024094185A1 (zh) * | 2022-11-04 | 2024-05-10 | 药捷安康(南京)科技股份有限公司 | Nlrp3炎症小体抑制剂及其应用 |
WO2024121086A1 (en) * | 2022-12-07 | 2024-06-13 | F. Hoffmann-La Roche Ag | Novel compounds as modulators of nlrp3 inhibition |
WO2024193541A1 (en) * | 2023-03-20 | 2024-09-26 | Insilico Medicine Ip Limited | Nlrp3 inflammasome inhibitors and uses thereof |
WO2024193699A1 (zh) * | 2023-03-23 | 2024-09-26 | 成都赜灵生物医药科技有限公司 | 三嗪类化合物及其用途 |
WO2024218100A1 (en) * | 2023-04-19 | 2024-10-24 | F. Hoffmann-La Roche Ag | Oxazolo[4,5-b]pyrazine and oxazolo[4,5-b]pyridine derivatives as nlrp3 inhibitors for the treatment of e.g. inflammatory diseases |
WO2024218188A1 (en) * | 2023-04-19 | 2024-10-24 | F. Hoffmann-La Roche Ag | 5-[5-(2-hydroxyphenyl)oxazolo[4,5-b]pyridin-2-yl]piperidin-2-one derivatives as nlpr3 inhibitors for the treatment of inflammatory diseases |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3920917A4 (en) * | 2019-02-04 | 2022-09-28 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING |
AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
CA3167023A1 (en) | 2020-01-22 | 2021-07-29 | F. Hoffmann-La Roche Ag | Sulfonimidamide compounds as nlrp3 modulators |
-
2022
- 2022-06-02 BR BR112023025318A patent/BR112023025318A2/pt unknown
- 2022-06-02 AU AU2022287224A patent/AU2022287224A1/en active Pending
- 2022-06-02 CA CA3216026A patent/CA3216026A1/en active Pending
- 2022-06-02 IL IL307201A patent/IL307201A/en unknown
- 2022-06-02 JP JP2023572751A patent/JP2024522494A/ja active Pending
- 2022-06-02 CR CR20230566A patent/CR20230566A/es unknown
- 2022-06-02 MX MX2023013998A patent/MX2023013998A/es unknown
- 2022-06-02 EP EP22731614.8A patent/EP4347571A1/en active Pending
- 2022-06-02 AR ARP220101456A patent/AR126053A1/es unknown
- 2022-06-02 WO PCT/EP2022/064995 patent/WO2022253936A1/en active Application Filing
- 2022-06-02 TW TW111120574A patent/TW202313577A/zh unknown
- 2022-06-02 PE PE2023003133A patent/PE20240928A1/es unknown
- 2022-06-02 KR KR1020237039328A patent/KR20240019083A/ko unknown
-
2023
- 2023-11-23 CL CL2023003491A patent/CL2023003491A1/es unknown
- 2023-11-29 CO CONC2023/0016212A patent/CO2023016212A2/es unknown
- 2023-11-30 US US18/524,678 patent/US20240132471A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL307201A (en) | 2023-11-01 |
WO2022253936A1 (en) | 2022-12-08 |
PE20240928A1 (es) | 2024-04-30 |
AR126053A1 (es) | 2023-09-06 |
CA3216026A1 (en) | 2022-12-08 |
CO2023016212A2 (es) | 2023-12-11 |
MX2023013998A (es) | 2023-12-11 |
KR20240019083A (ko) | 2024-02-14 |
TW202313577A (zh) | 2023-04-01 |
JP2024522494A (ja) | 2024-06-21 |
AU2022287224A1 (en) | 2023-09-21 |
US20240132471A1 (en) | 2024-04-25 |
CL2023003491A1 (es) | 2024-05-24 |
BR112023025318A2 (pt) | 2024-02-27 |
EP4347571A1 (en) | 2024-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20230566A (es) | Derivados de triazina y su uso en el tratamiento del cáncer | |
MX2021011209A (es) | Novedosos inhibidores de molécula pequeña de factores de transcripción tead. | |
PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
EP4374858A3 (en) | Benzimidazolone derived inhibitors of bcl6 | |
TW200745004A (en) | Novel compounds, their preparation and use | |
MX2023012907A (es) | Inhibidores de inflamasoma proteina 3 que contiene dominios de pirina (nlrp3). | |
ZA202201364B (en) | Deuterated compounds for use in the treatment of cancer | |
CY1109906T1 (el) | Παραγωγα c3-kyano εποθιλονης | |
EP4371562A3 (en) | 2-quinolone derived inhibitors of bcl6 | |
PH12021550382A1 (en) | Tetrahydropyridopyrimidine derivatives as ahr modulators | |
MX2010003365A (es) | Derivados de tiazol para el tratamiento de cancer. | |
CR20230382A (es) | Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer | |
TW200630374A (en) | Thiazolyldihydroindazoles | |
CR20230410A (es) | Derivados novedosos de pirimidin-2-il-sulfonamida | |
CR20210460A (es) | Compuestos útiles en la terapia del vih | |
EP4233865A3 (en) | Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers | |
MX2020008746A (es) | Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado. | |
MX2023011715A (es) | Compuestos de oxoisoindolina sustituidos con piridinilo. | |
MX2021009426A (es) | Derivados de indazolil-isoxazol para el tratamiento de enfermedades tales como cancer. | |
WO2023107574A3 (en) | Lipid-based compositions and methods thereof | |
MX2024002409A (es) | Terapias contra el cancer. | |
MX2022011646A (es) | Celulas t v delta1+ para el tratamiento de neoplasias mieloides. | |
MXPA03005374A (es) | Carbazoles antitumorales. | |
MX2024003028A (es) | Derivados de 6 aza quinolina y usos relacionados. | |
WO2023049808A3 (en) | Small molecule inhibitors of tead-yap |